Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Combination strategies to overcome drug resistance in FLT+ acute myeloid leukaemia

11 Aug 2023

Abstract excerpt

BACKGROUND: Acute myeloid leukaemia (AML) remains difficult to treat despite the development of novel formulations and targeted therapies. Activating mutations in the FLT3 gene are common among patients and make the tumour susceptible to FLT3 inhibitors, but resistance to such inhibitors develops quickly. METHODS: -AML, and studied the development of resistance using a newly developed protocol. Combinations of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Advanced Breast Cancer Therapies
Share to Cancer-related Molecular Pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37568211
DOI: 10.1186/s12935-023-03000-x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Combination strategies to overcome drug resistance in FLT+ acute myeloid leukaemiaPMID 37568211Read ↗

AMG 925 is a dual FLT3/CDK4 inhibitor with the potential to overcome FLT3 inhibitor resistance in acute myeloid leukemia.Semantic proximity Read ↗

FLT3 Inhibitors in Acute Myeloid Leukemia: Challenges and Recent Developments in Overcoming Resistance.Semantic proximity Read ↗

The multi-kinase inhibitor CG-806 exerts anti-cancer activity against acute myeloid leukemia by co-targeting FLT3, BTK, and Aurora kinasesSemantic proximity Read ↗

Combined inhibition of PI3Kδ and FLT3 signaling exerts synergistic antitumor activity and overcomes acquired drug resistance in FLT3-activated acute myeloid leukemia.Semantic proximity Read ↗

Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6.Semantic proximity Read ↗

Can FLT3 inhibitors overcome resistance in AML?Semantic proximity Read ↗

Improved efficacy of quizartinib in combination therapy with PI3K inhibition in primary FLT3-ITD AML cells.Semantic proximity Read ↗

Synergistic cytotoxicity of dual PI3K/mTOR and FLT3 inhibition in FLT3-ITD AML cells.Semantic proximity Read ↗

CDK4/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1T315I+ clones in TKI-resistant CML.Semantic proximity Read ↗

The multi-kinase inhibitor CG-806 exerts anti-cancer activity against acute myeloid leukemia by co-targeting FLT3, BTK, and aurora kinases.Semantic proximity Read ↗

Inhibitors of class I HDACs and of FLT3 combine synergistically against leukemia cells with mutant FLT3Semantic proximity Read ↗

Effect of Quizartinib on the Resistance of Acute Myeloid Leukemia Cells with FLT3-ITD-Positive and FLT3-ITD-Negative Phenotypes to the TRAIL-Induced Apoptosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.